This episode was recorded live from the Ai4 conference podcast pavilion, Sam sat down with Alex Zhavoronkov, Founder & CEO of Insilico Medicine, about what it actually takes to turn AI-generated molecules into approved drugs.

What's Covered:

From Laughed-Out-of-the-Room to 33 Candidates — Alex pitched generative AI for drug design in 2015 and got dismissed. Today: 33 developmental candidates in six years, zero failed toxicity studies, and deals with Eli Lilly, Takeda, Servier, and SK Bio at a pace of nearly one per month.

The Real Bottleneck — "It's not about a story. Many people in our field love to tell a story, but they don't have a single drug in the clinic discovered by AI." Alex's direct take on separating hype from results in AI drug discovery.

 ...